Central Nervous System Progression/Relapse in Mature T- and NK-Cell Lymphomas

被引:5
作者
Bhansali, Rahul S. [1 ]
Barta, Stefan K. [1 ]
机构
[1] Hosp Univ Penn, Dept Med, Div Hematol & Oncol, Philadelphia, PA 19104 USA
基金
英国科研创新办公室; 美国国家卫生研究院;
关键词
T-cell; NK-cell; lymphoma; lymphocyte; relapse; progression; central nervous system; prophylaxis; NON-HODGKINS-LYMPHOMA; RISK-FACTORS; LEUKEMIA-LYMPHOMA; COMBINATION CHEMOTHERAPY; BRENTUXIMAB VEDOTIN; NATURAL-HISTORY; DENDRITIC CELLS; FAS LIGAND; NASAL-TYPE; PHASE-II;
D O I
10.3390/cancers15030925
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Mature T- and NK-cell neoplasms are a heterogeneous group of disease entities that comprise about 15% of non-Hodgkin lymphomas. These subtypes are often aggressive, especially in the relapsed/refractory setting. In particular, central nervous system progression/relapse is a rare but devastating outcome for these patients. Moreover, relative infrequency and heterogeneity of tumor biology have precluded the ability to establish standards of care for prophylaxis and treatment of patients with secondary central nervous system involvement. This review describes the epidemiology and risk factors of central nervous system progression/relapse in patients with mature T- and NK-cell lymphomas and discusses the role of prophylaxis and therapy. Non-Hodgkin lymphomas (NHL) are cancers of mature B-, T-, and NK-cells which display marked biological heterogeneity between different subtypes. Mature T- and NK-cell neoplasms are an often-aggressive subgroup of NHL and make up approximately 15% of all NHL. Long-term follow up studies have demonstrated that patients with relapsed/refractory disease have dismal outcomes; in particular, secondary central nervous system (CNS) involvement is associated with higher mortality, though it remains controversial whether this independently confers worse outcomes or if it simply reflects more aggressive systemic disease. Possible risk factors predictive of CNS involvement, such as an elevated lactate dehydrogenase and more than two sites of extranodal involvement, may suggest the latter, though several studies have suggested that discrete sites of anatomic involvement or tumor histology may be independent risk factors as well. Ultimately, small retrospective case series form the basis of our understanding of this rare but devastating event but have not yet demonstrated a consistent benefit of CNS-directed prophylaxis in preventing this outcome. Nonetheless, ongoing efforts are working to establish the epidemiology of CNS progression/relapse in mature T- and NK-cell lymphomas with the goal of identifying clinicopathologic risk factors, which may potentially help discern which patients may benefit from CNS-directed prophylactic therapy or more aggressive systemic therapy.
引用
收藏
页数:21
相关论文
共 50 条
[31]   Cytotoxic T-cell and NK-cell Lymphomas Current Questions and Controversies [J].
Swerdlow, Steven H. ;
Jaffe, Elaine S. ;
Brousset, Pierre ;
Chan, John K. C. ;
de Leval, Laurence ;
Gaulard, Philippe ;
Harris, Nancy Lee ;
Pileri, Stefano ;
Weiss, Lawrence M. .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2014, 38 (10) :E60-E71
[32]   Education and Empowering Special Forces to Eradicate Secret Defectors: Immune System-Based Treatment Approaches for Mature T- and NK-Cell Malignancies [J].
Braun, Till ;
Schrader, Alexandra .
CANCERS, 2023, 15 (09)
[33]   The spectrum of intestinal mature T- and NK-cell neoplasms in a tertiary center in Taiwan with a high frequency of perforation [J].
Wang, Ren Ching ;
Chen, Bo-Jung ;
Yuan, Chang-Tsu ;
Ho, Chung-Han ;
Chuang, Wen -Yu ;
Chen, Shang -Wen ;
Chang, Julia Hueimei ;
Yu, Wei-Hsiang ;
Chuang, Shih-Sung .
PATHOLOGY RESEARCH AND PRACTICE, 2022, 240
[34]   NK-cell Lineage Predicts Poor Survival in Primary Intestinal NK-cell and T-cell Lymphomas [J].
Chuang, Shih-Sung ;
Chang, Sheng-Tsung ;
Chuang, Wen-Yu ;
Huang, Wan-Ting ;
Hsieh, Pin-Pen ;
Tsou, Mei-Hua ;
Liao, Yung-Liang ;
Lin, Shu-Hui ;
Hsieh, Yen-Chuan ;
Lu, Chin-Li ;
Sheu, Ming-Jen ;
Liu, Hongxiang .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2009, 33 (08) :1230-1240
[35]   Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study [J].
Bachy, Emmanuel ;
Savage, Kerry J. ;
Huang, Huiqiang ;
Kwong, Yok-Lam ;
Gritti, Giuseppe ;
Zhang, Qingyuan ;
Liberati, Anna Marina ;
Cao, Junning ;
Yang, Haiyan ;
Hao, Siguo ;
Hu, Jianda ;
Zhou, Keshu ;
Petrini, Mario ;
Russo, Filomena ;
Zhang, Huilai ;
Sang, Wei ;
Ji, Jie ;
Ferreri, Andres Jose Maria ;
Damaj, Gandhi Laurent ;
Liu, Hui ;
Zhang, Wei ;
Ke, Xiaoyan ;
Ghiggi, Chiara ;
Huang, Sha ;
Li, Xiaotong ;
Yao, Hui ;
Paik, Jason ;
Noveotny, William ;
Zhou, Wenxiao ;
Zhu, Hongji ;
Zinzani, Pier Luigi .
BLOOD ADVANCES, 2023, 7 (16) :4435-4447
[36]   Controversies in autologous and allogeneic hematopoietic cell transplantation in peripheral T/NK-cell lymphomas [J].
Shustov, Andrei .
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2013, 26 (01) :89-99
[37]   Extranodal NK/T-Cell Lymphoma Occurring Primarily in the Eyes and with Central Nervous System Relapse [J].
Wei, Chong ;
Zhang, Lu ;
Zhang, Wei ;
Zhou, Daobin .
CANCER MANAGEMENT AND RESEARCH, 2021, 13 :6579-6583
[38]   Progress in T-cell and NK-cell malignancies [J].
Medeiros, L. Jeffrey .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2007, 127 (04) :494-495
[39]   Analyses of dose-response in radiotherapy for patients with mature T/NK-cell lymphomas according to the WHO classification [J].
Sakata, Koh-ichi ;
Fuwa, Nobukazu ;
Kodaira, Takeshi ;
Aratani, Kazunori ;
Ikeda, Hikaru ;
Takagi, Masaru ;
Nishio, Masamichi ;
Satoc, Masaaki ;
Nakamura, Shigeo ;
Satoh, Hidetoshi ;
Hareyama, Masato .
RADIOTHERAPY AND ONCOLOGY, 2006, 79 (02) :179-184
[40]   Diagnostic approach to T- and NK-cell lymphoproliferative disorders in the gastrointestinal tract [J].
Susan, Swee-Shan Hue ;
Ng, Siok-Bian ;
Wang, Shi ;
Tan, Soo-Yong .
SEMINARS IN DIAGNOSTIC PATHOLOGY, 2021, 38 (04) :21-30